Aversive memories associated with drug withdrawal may contribute to persistent drug seeking. Molecular mechanisms that are critical for aversive memory formation have yet to be elucidated. Recently, we showed in a rat conditioned place aversion (CPA) model that synaptic actin polymerization in the amygdala were required for aversive memory information. Here, we demonstrated that actin polymerization within the amygdala triggered transportation of activity-regulated cytoskeletal-associated protein (Arc/Arg3.1) into amygdalar synapses. Increased synaptic Arc/Arg3.1 expression contributed to aversive memory formation by regulating synaptic AMPA receptor (AMPAR) endocytosis, as in vivo knockdown of amygdalar Arc/Arg3.1 with Arc/Arg3.1-shRNA prevented both AMPAR endocytosis and CPA formation. We also demonstrated that conditioned morphine withdrawal led to induction of LTD in the amygdala through AMPAR endocytosis. We further demonstrated that Arc/Arg3.1-regulated AMPAR endocytosis was GluR2 dependent, as intraamygdala injection of Tat-GluR2 3Y , a GluR2-derived peptide that has been shown to specifically block regulated, but not constitutive, AMPAR endocytosis, prevented AMPAR endocytosis, LTD induction, and aversive memory formation. Therefore, this study extends previous studies on the role of actin polymerization in synaptic plasticity and memory formation by revealing the critical molecular events involved in aversive memory formation as well as LTD induction, and by showing that Arc/Arg3.1 is a crucial mediator for actin polymerization functions, and, thus, underscores the unknown details of how actin polymerization mediates synaptic plasticity and memory.
Introduction
Opiate addiction is the chronic relapsing disorder characterized by compulsive drug taking (Kenny, 2007) . The maintenance of compulsive use of the drugs is substantially motivated by the negative reinforcing effects of drug withdrawal (Wikler and Pescor, 1967; Hutcheson et al., 2001) . Conditioned place aversion (CPA), a model of Pavlovian associative learning, is a sensitive animal model for measurement of the negative affective components of morphine withdrawal in dependent animals (Mucha et al., 1982) . The amygdala is a crucial component of the neuronal circuitry mediating associative learning and also is a critical mediator of aversively emotional learning (LeDoux, 2000) . Using a CPA model, we revealed recently that actin polymerization in the amygdala underlies the formation of aversive memories associated with morphine withdrawal ). However, the molecular mechanisms underlying such an effect of actin polymerization remain to be established.
Cytoskeletal actin is the major structural component of the dendritic spine (Halpain, 2000) , and its dynamics between G-actin and F-actin, namely actin rearrangements, have been shown to play a role in synaptic and behavioral plasticity (Toda et al., 2006; Rex et al., 2010) . The cytoskeletal actin could contribute to synaptic plasticity by several possibilities (Halpain, 2000; Schafer, 2002) . One potential possibility may be the regulation of AMPA receptor (AMPAR) trafficking, as several lines of evidence support a role for actin polymerization in clathrin-mediated endocytosis (Schafer, 2002; Yarar et al., 2005) . Regulation of AMPAR endocytosis and recycling is a principal mechanism for activity-dependent synaptic plasticity (e.g., LTP, LTD, and ho-meostatic plasticity) (Bredt and Nicoll, 2003; Anggono and Huganir, 2012) . AMPA receptor-mediated glutamate transmission and AMPAR trafficking in the nucleus accumbens and prefrontal cortex also play a central role in some behavioral adaptations (e.g., behavioral sensitization, drug-or cue-induced relapse to drug-seeking) resulting from addictive drug exposure (Brebner et al., 2005; Van den Oever et al., 2008; Kalivas, 2009 ). Although there is growing evidence that actin polymerization plays a critical role in clathrin-mediated endocytosis in many cell types, little is known about the role of actin polymerization within synapses in activity-dependent AMPAR endocytosis and the mechanisms underlying actin polymerization regulation of AMPAR endocytosis.
In addition to dependence on actin polymerization in the synapses, synaptic plasticity and memory formation also rely on gene and protein synthesis at synapses (Steward and Worley, 2002; Kelleher et al., 2004) . The activity-regulated cytoskeletalassociated gene Arc, also known as Arg3.1, is necessary for the stabilization of the synaptic plasticity and for the some forms of long-term memory (Guzowski et al., 2000; Plath et al., 2006) . Arc/Arg3.1 has been shown to interact with endophilin2/3 and dynamin to modulate AMPAR endocytosis, thus allowing Arc/ Arg3.1 to influence synaptic strength and excitability as well as synaptic homeostasis Rial Verde et al., 2006; Shepherd et al., 2006) . Although these recent in vitro studies have demonstrated a role of Arc/Arg3.1 in mediation of AMPAR endocytosis, few studies have examined whether a similar effect of Arc/Arg3.1 on AMPAR endocytosis also occurs in vivo in response to stimulus known to cause synaptic plasticity and memories, and whether this regulatory process plays an essential role in synaptic plasticity and memory formation. In the present study, using the CPA model, we tested the hypothesis that actin polymerization and Arc/Arg3.1 expression within synapses may have a causal relation to function, and their interaction may be required for the regulation of postsynaptic AMPAR endocytosis, thereby contributing to the synaptic plasticity and memory formation.
Materials and Methods

Animals
Sprague Dawley male rats weighting 220 -300 g were obtained from the Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). Rats were housed 2-3 per cage and maintained on a 12 h light/ dark cycle with access to food and water ad libitum. All experimental procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Drugs and antibodies
Morphine hydrochloride was purchased from Qinghai Pharmaceutical General Factory. Naloxone hydrochloride, D-AP5, and CNQX were supplied by Sigma Aldrich. Latrunculin A and Y27632 were obtained from Calbiochem. Tat-GluR2 3Y and Tat-GluR2 3S were obtained from AnaSpec. The antibodies of anti-actin were purchased from Sigma-Aldrich and diluted 1:5000, and the antibodies of anti-Arc were obtained from Santa Cruz Biotechnology and diluted 1:1000 for Western blot analysis. The antibodies of anti-GluR1 and anti-GluR2 were purchased from Millipore and diluted 1:5000 for Western blot analysis.
Conditioned place aversion
The CPA apparatus (Anilab Software and Instruments) was divided into two equal-sized compartments [55 cm (length) ϫ 30 cm (width) ϫ 30 cm (height)] separated by a removable board (10 ϫ 10 cm), which allowed rats free access to each compartment. Two compartments were distinguished by visual and tactile cues: the one was a blank wall with a smooth floor, whereas the other was a white wall with a textured floor. These distinctive tactile and visual stimuli served as the conditioning cues. Conditioned morphine withdrawal procedure has been described previously . Briefly, animals experienced three phases: preconditioning, conditioning, and testing. In the preconditioning phase, rats were allowed to freely explore the entire apparatus for 15 min. Time spent in each compartment was recorded, and those showing a strong unconditioned aversion (one compartment Ͼ720 s) for either compartment were eliminated from the study. Conditioning took place over the next 2 d. On the first day, the rats were injected with saline (1 ml/kg, s.c.) and then returned to home cages. Four hours later, they were given saline again and then confined to either compartment in a counterbalanced manner for 30 min. On the second day, the rats were injected with either morphine (10 mg/kg, s.c.) or saline (1 ml/kg, s.c.) and then returned to their home cages. Four hours later, they were injected with either naloxone (0.3 mg/kg, s.c.) or saline and then confined to the compartment opposite to the first day for 30 min. This compartment will be referred to as the "drug treatment-paired compartment." Testing phase took place 24 h after the conditioning trial, and all rats were allowed to freely explore the entire apparatus for 15 min; the amount of time spent in each compartment was recorded. The CPA score represents the time in the drug treatment-paired compartment during the testing phase minus that during the preconditioning phase. For Western blotting analysis, rats were perfused immediately on the second day of CPA conditioning.
Subcellular fractionation
Rats were anesthetized and killed by decapitation. Coronal brain sections (1 mm thick) were obtained using a rat brain slicer (Braintree Scientific). Both sides of the amygdala were punched from brain slices using a bluntend, 17-gauge syringe needle (1 mm inner diameter). The tissue of amygdala punched included most of the central and lateral, basolateral nuclei of the amygdala. In all subsequent procedures, the tissues were maintained at 4°C. A crude synaptosomal fraction was made according to the procedure of Whittaker and Gray (1962) . Briefly, the tissue was homogenized with 10 strokes with a Teflon pestle in 10 volumes of 0.32 M sucrose. The homogenate was centrifuged at 1000 ϫ g for 10 min, and the pellet was discarded. The supernatant was then centrifuged at 17,000 ϫ g for 30 min. The resultant P2 pellet was washed in an equal volume of 0.32 M sucrose and recentrifuged at 17,000 ϫ g for another 30 min. The pellet was used as intact synaptosomes.
Subcellular fractionation and actin analysis of the dissected brain tissue was performed as described previously . Briefly, the crude synaptosome fraction was dissolved hypo-osmotically and centrifuged at 25,000 ϫ g for 25 min to precipitate a synaptosomal membrane fraction (LP1). To separate F-actin and G-actin, LP1 was lysed in buffer A (1% Triton X-100, 20 mM HEPES, 100 mM NaCl, 2 mM EDTA, 5 mM NaF, 1 mM Na 3 VO 4 , 1 mM aprotinin, 1 mM leupeptin, 1 mM PMSF, pH7.2) for 1 h and centrifuged at 10,000 ϫ g for 20 min. Pellets were dissolved in buffer B (15 mM HEPES, 0.15 mM NaCl, 1% SDS, 10 mM EDTA, 1 mM DTT, 5 mM NaF, 1 mM Na 3 VO 4 , 1 mM aprotinin, 1 mM leupeptin, 1 mM PMSF, pH7.5) for 1 h and centrifuged at 10,000 ϫ g for 20 min. The G-actin fraction (the first supernatant) and the F-actin fractin (the second supernatant) were collected.
Immunoblotting of Arc/Arg3.1
Equal amounts of protein were electrophoresed on 12% SDSpolyacrylamide gels and transferred to nitrocellulose membranes. Arc was detected using a monoclonal mouse anti-arc serum (sc-17839, Santa Cruz Biotechnology) at a 1:1000 dilution in TBS containing 5% nonfat dry milk and 0.05% Tween-20. After incubation with HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology) at a 1:2000 dilution, bands were developed with a chemiluminescent substrate (RPN2132, GE Healthcare). The immunopositive signals were quantified by Quantity One software (Bio-Rad).
Intracerebral microinjection
Rats were anesthetized using sodium pentobarbital (50 mg/kg, i.p.), treated with atropine sulfate (0.2 mg/kg, i.p.), and then placed in a stereotaxic apparatus (Narishige) with the incisor bar set at 3.3 mm. Rats were implanted bilaterally with guide cannulae (26 gauge) in the amygdala (AP, Ϫ2.8 mm; ML, Ϯ4.5 mm; DV, Ϫ6.0 mm). Bilateral microinfusions were made through 31 gauge injection cannulae (2.0 mm beyond the tip of guide cannulae), which was connected to a 10 l microsyringe mounted in the microinfusion pump (Harvard Apparatus) for no less than 2 min and given an additional 2 min for drug diffusion. Latrunculin A was dissolved in DMSO (25 g/l stock solution) and diluted in PBS to a final concentration of 0.5 g/l. Latrunculin A was bilaterally microinjected into the amygdala 10 min before pairing. Y27632 and D-AP5 were dissolved in PBS before use and were bilaterally microinjected into the amygdala 30 and 10 min before pairing, respectively. CNQX was dissolved in DMSO (50 g/l stock solution) and diluted in PBS to a final concentration of 60 nmol/l, and was bilaterally microinjected into the amygdala 10 min before pairing. Tat-GluR2 3Y and Tat-GluR2 3S were dissolved in PBS to a concentration of 30 pmol/l, and were bilaterally microinjected into the amygdala 60 min before pairing. The doses of latrunculin A, Y27632, D-AP5, CNQX, Tat-GluR2 3Y , and Tat-GluR2 3S were chosen based on pilot experiments and previous studies.
Histology
After behavior testing, rats were deeply anesthetized with sodium pentobarbital and perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in PBS. The brains were removed and stored in a 30% sucrose/PBS solution for 2-3 d. Coronal sections (30 m thick) were cut on a cryostat (Leica), stained with cresyl violet, and then examined by light microscopy to determine injection sites.
Lentivirus construction and infection
Production and testing of recombinant lentiviral vectors. The lentiviral plasmid pSicoR was purchased from Addgene, and oligos coding for the various shRNAs were annealed and cloned into HpaI-XhoI-digested pSicoR vectors. The following target shRNA regions were chosen: ARC, GCTGATGGCTACGACTACA; negative control, TTCTCCGAACGT-GTCACGT. Lentiviruses were generated essentially as described in the following. Briefly, 5 g of lentiviral vector and 2.5 g of each packaging vector were cotransfected in 293T cells by using the FuGENE 6 reagent (Roche Diagnostics). Supernatants were collected 36 -48 h after transfection, filtered through a 0.4 m filter. High-titer stocks were prepared by an initial ultracentrifugation for 1 h at 23,000 rpm (SW-28 rotor; Beckman Coulter) and a secondary tabletop centrifugation at 13,000 ϫ g for 30 min. Viral pellet was resuspended in 1% BSA/PBS and stored at Ϫ80°C. Viral titers were determined by infection of HEK293T cells, and GFP-positive cells were visualized by fluorescent microscopy. After concentration, viral titers were 5 ϫ 10 8 Ϫ2 ϫ 10 9 transducing units (TU)/ml. The high-titer lentiviral stocks were then used directly to infect cultured neurons or microinject into the rat brains.
Stereotaxic vector injections into rat amygdala. Rats were anesthetized using sodium pentobarbital (50 mg/kg, i.p.), treated with atropine sulfate (0.2 mg/kg, i.p.), and then placed in a stereotaxic apparatus (Narishige) with the incisor bar set at 3.3 mm. Rats were implanted bilaterally with guide cannulae (26 gauge) in the amygdala (AP, Ϫ2.8 mm; ML, Ϯ4.5 mm; DV, Ϫ6.0 mm). Lentivirus (5 ϫ 10 8 Ϫ1 ϫ 10 9 TU/ml) was stereotaxically injected into the amygdala (3 l/site) over 5 min using a 31 gauge injection cannula (2.0 mm beyond the tip of guide cannula), which was connected to a 10 l microsyringe mounted in the microinfusion pump (Harvard Apparatus). The needle was retained in place for another 5 min before being withdrawn at 1 mm/min. At 2-3 weeks post-injection, anesthetized rats were perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in PBS. The brains were removed and postfixed in 4% paraformaldehyde for 24 h and then cryoprotected in 30% sucrose. Frozen coronal sections (30 m) were made through the amygdala using a cryostat (Leica); the fluorescence was examined by fluorescence microscopy (Olympus).
Surface receptor cross-linking with BS 3
Surface and intracellular GluR1-and GluR2-containg AMPAR levels were determined with a protein cross-linking assay as previously described (Boudreau and Wolf, 2005) , with minor modifications. Briefly, rat brain tissue was incubated with protein cross-linking reagent bis (sulfosuccinimidyl) suberate (BS 3 ; Pierce Biotechnology) to determine S (surface) and I (intracellular) levels of receptor subunit proteins. After the last pairing of naloxone or saline, rats were decapitated. Brains were rapidly removed, and coronal brain sections (500 m thick) containing the amygdala were obtained using a rat brain slicer (Braintree Scientific). Slices were then added to 2 ml eppendorf tubes containing 1 ml of artificial CSF (ACSF) spiked with 2 mM BS 3 . The ACSF contained the following (in mM): NaCl 120, KCl 2.5, NaHCO 3 26, NaH 2 PO 4 1.25, CaCl 2 2, MgSO 4 2, and D-glucose 10, and was bubbled with the gas mixture of 95% O 2 and 5% CO 2 for at least 1 h. Incubation with gentle agitation proceeded for 30 min at 4°C. Cross-linking was terminated by quenching the reaction with 100 mM glycine (10 min, 4°C). The slices were pelleted for 2 min at 14,000 rpm, and the supernatant was discarded. Pellets were resuspended in ice-cold lysis buffer containing protease and phosphatase inhibitors and homogenized rapidly by sonicating, samples were centrifuged at 14,000 rpm for 2 min, and the supernatant fraction were collected for Western blotting. Total protein concentration of lysates was determined by The Precision Red Advanced Protein Assay (Cat. # ADV02, Cytoskeleton). Samples were aliquoted and stored at Ϫ80°C for future analysis.
Electrophysiology
After different training according to experimental design, the rats were deeply anesthetized with diethyl ether and the brain was rapidly removed and immersed in ice-cold ACSF continuously bubbled with the gas mixture of 95% O 2 and 5% CO 2 . Amygdalar slices were cut coronally and then transferred to an incubation chamber containing ACSF heated to 36 Ϯ 1°C for 20 min recovery and then maintained at room temperature (22Ϫ25°C). Slices were placed in a recording chamber and perfused by oxygen saturated ACSF with a flow rate of 4 -5 ml/min. Recordings were made just below the site of termination of thalamic fibers terminating in the lateral amygdala by a glass recording electrode filled with ACSF (4 -6 M⍀). The stimulation was adjusted for each slice to produce reliable field potential that was approximately 50% of maximal response. LTD was elicited by low-frequency stimuli (LFS, 1 Hz, 900 pulses) after baseline was stably recorded for at least 20 min at a frequency of 0.033 Hz.
Data analysis
The data were analyzed with two-tailed Student's t tests, or one-way ANOVA, and then followed by Newman-Keuls post hoc tests when appropriate. Differences with p Ͻ 0.05 were considered statistically significant. The results are presented as mean Ϯ SEM.
Results
Actin polymerization occurred in the amygdala through RhoA-ROCK signaling and depended on NMDA receptor activation after conditioned morphine withdrawal Our previous study reveals that conditioned morphine withdrawal (CMW) induces synaptic actin polymerization in the amygdala of rats, characterized by a significant elevation of polymerized F-actin and a decrease of monomeric G-actin, which contributes to CPA formation ). To investigate mechanisms by which actin polymerization modulates CPA formation, in this study, we first determined molecular events involved in the actin polymerization. Previous studies have demonstrated that actin polymerization in the hippocampus induced by HFS depends on NMDA receptor activation and can be blocked by Rho kinase (ROCK) inhibitors (Fukazawa et al., 2003; Huang et al., 2007) . To determine whether actin polymerization in the amygdala induced by CMW also depends on NMDA receptor activation and is mediated by ROCK, we examined the effects of Y27632, a highly selective and potent ROCK inhibitor, and D-AP5, an NMDA-receptor antagonist, on synaptic actin polymerization in the amygdala induced by CMW. Consistent with our previous observations, a significant synaptic actin polymerization in the amygdala was observed in rats 1 h after CMW ( Fig. 1 A, B) . Bilateral microinjection of either Y27632 (8.56 g/ 0.5 l/side) or D-AP5 (4 g/0.5 l/side) into the rat amygdala 30 min or 10 min before CMW significantly blocked synaptic actin polymerization induced by CMW (Y27632, 41.51 Ϯ 11.07% of control, n ϭ 4, F (2,11) ϭ 18.82, p ϭ 0.0006; D-AP5, 54.61 Ϯ 12.93% of control, n ϭ 5, F (2,14) ϭ 22.04, p Ͻ 0.0001; Fig. 1 A, B) , indicating that amygdalar synaptic actin polymerization is involved in the RhoA-ROCK signaling pathway and depended on NMDA receptor activation.
Our previous study also shows that prevention of actin polymerization by the F-actin polymerization inhibitor latrunculin A suppresses CPA formation , indicative of the involvement of actin polymerization in CPA formation. We further confirmed this result in the present study by delivering the ROCK inhibitor Y27632 into the amygdala via local microinjection. In support of our previous findings, bilateral microinjection of Y27632 (8.56 g/0.5 l/side) into the amygdala prepairing but not postpairing significantly attenuated place aversion behaviors compared with vehicle-microinjected group (aversion score: vehicle, Ϫ377.0 Ϯ 61.6 s, n ϭ 14; prepairing, Ϫ66.5 Ϯ 42.6 s, n ϭ 9; postpairing, Ϫ312.0 Ϯ 40.4 s, n ϭ 7; F (2,29) ϭ 7.139, p ϭ 0.0032; Fig. 1C ), supporting that amygdalar synaptic actin polymerization is required for CPA formation. Additionally, NMDA-receptor antagonists such as D-AP5 and MK-801 have also been shown to suppress morphine withdrawal-induced CPA formation (Watanabe et al., 2002; Kawasaki et al., 2005) . Taken together, the results of our present and previous studies clearly indicate that synaptic actin polymerization within the amygdala plays a critical role in CPA formation, and also show that actin polymerization is dependent on NMDA receptor activation and is involved in the RhoA-ROCK signaling pathway.
Arc/Arg3.1 protein expression was increased in the amygdala in response to both conditioned and unconditioned morphine withdrawal, but its accumulation at synapses was induced only by conditioned morphine withdrawal Arc/Arg3.1 mRNA expression and localization at active synapse are induced by experimental paradigms known to cause synaptic plasticity and memories (Lyford et al., 1995; Steward and Worley, 2001 ). Enhancement of Arc/Arg3.1 protein at active synapses is critically involved in processes of synaptic plasticity underlying behavioral memories (Guzowski et al., 2000; Plath et al., 2006) . Our previous studies also demonstrate that CMW induces the expression of Arc/Arg3.1 protein in the amygdala, mainly in the basolateral nucleus (BLA) and the central nucleus (CeA) Li et al., 2009) . To address the role of the interaction of Arc/Arg3.1 protein expression and actin polymerization in CPA formation, we first examined colocalization of Arc/Arg3.1 protein with F-actin at amygdalar synapses following CMW. The distribution of Arc/Arg3.1 was analyzed by subcellular fractionation of amygdalar lysates, followed by immunoblotting using Arc/Arg3.1 antibody. PSD-95, a core structural component of the PSD, was used as a marker of synaptic sites. Immunoblotting showed that Arc/Arg3.1 protein highly accumulated in the synaptic fractions of amygdalar lysates (Fig. 2 A) . The colocalization of Arc/Arg3.1 protein with F-actin was detected by fractionalizing different actin components, followed by immunoblotting using Arc/Arg3.1 antibody. Arc/Arg3.1 protein was found to have high concentrations in the F-actin fractions (Fig. 2 B) , confirming that Arc/Arg3.1 colocalized with F-actin at synapses. The results are consistent with previous reports that Arc/Arg3.1 mRNA and protein cosediment with crude filamentous actin (F-actin) and localize at the PSD of excitatory synapses (Lyford et al., 1995; Husi et al., 2000) .
Next, we determined whether the colocalization of Arc/Arg3.1 protein with F-actin at synapses was dependent on CMW. To this end, we detected Arc/Arg3.1 protein expression in both amygdalar homogenates and synaptosomal fractions of the amygdala isolated from rats that underwent CMW or unconditioned morphine withdrawal (UMW). A significant elevation of Arc/Arg3.1 protein expression was detected in the amygdalar homogenates isolated from rats 0.5 and 1 h after CMW (control, 100 Ϯ 1.97%, n ϭ 6; 0.5 h, 197.8 Ϯ 16.8%, n ϭ 5; 1 h, 212 Ϯ 43.1%, n ϭ 5; F (2,15) ϭ 6.324, p ϭ 0.0121; Fig. 2C , left) and UMW (control, 100 Ϯ 10.0%; 0.5 h, 196.0 Ϯ 30.5%; 1 h, 204.9 Ϯ 22.5%; n ϭ 5, F (2,14) ϭ 6.620, p ϭ 0.0115; Fig. 2C , right), indicating that CMW and UMW both induced Arc/Arg3.1 protein expression. However, a significant increase in Arc/Arg3.1 protein expression in the synaptosomal membrane fractions of amygdala was detected only in the rats that underwent CMW (CMW: control, 100 Ϯ 16.2%; 0.5 h, 113.5 Ϯ 14.4%; 1 h, 247.6 Ϯ 40.7%; n ϭ 6, F (2,17) ϭ 9.398, p ϭ 0.0023; UMW: control, 100 Ϯ 5.4%, n ϭ 5; 0.5 h, 87.4 Ϯ 11.7%, n ϭ 5; 1 h, 96.4 Ϯ 13.4%, n ϭ 4; F (2,13) ϭ 0.417, p ϭ 0.6688; Fig. 2 D) , indicating that CMW but not UMW induced the accumulation of Arc/Arg3.1 protein at synapses, and also suggesting that CMW was required for increase in Arc/Arg3.1 protein at synapses. Additionally, although increase in Arc/ Arg3.1 expression in the amygdala was observed at 0.5 h after CMW, the accumulation of Arc/Arg3.1 expression at synapses was detected at 1 h but not 0.5 h after CMW (Fig. 2 D, left) , suggesting that there is a process of translocation of Arc/Arg3.1 from neuronal soma to synapses. These results are consistent with previous findings that experimental paradigms known to cause synaptic plasticity and memories trigger translocation of Arc/Arg3.1mRNA to active synapse (Lyford et al., 1995; Steward and Worley, 2001 ).
Increases in Arc/Arg3.1 protein expression at synapses by conditional morphine withdrawal was disrupted by blockade of actin polymerization The data present above demonstrated that both CMW and UMW induced Arc/Arg3.1 protein expression in the amygdala, but only CMW induced the enhancement of Arc/Arg3.1 protein at synapses. Additionally, our previous study also found that CMW but not UMW elicited actin polymerization in the synapses of the amygdala ). Since the F-actin has been shown to serve as a path for local mRNA trafficking within the dendritic spine (Kaech et al., 2001 ), the elevation of Arc/Arg3.1 protein and actin polymerization occurring in the same synapses in response to CMW raises the possibility that actin polymerization may play a role in the targeting Arc/Arg3.1 mRNA to synapses. To test this hypothesis, we examined the effect of blockade of actin polymerization on accumulation of Arc/Arg3.1 protein at synapses. Since the RhoA kinase inhibitor Y27632, the F-actin polymerization inhibitor latrunculin A, and the NMDA receptor antagonist D-AP5 all abolish actin polymerization induced by CMW (Fig.  1 A, B) , we thus assessed the effects of local injection of Y27632, latrunculin A, or D-AP5 on accumulation of Arc/Arg3.1 protein at synapses trigged by CMW. As presented in Figure 3 , bilateral microinjection of Y27632 (8.56 g/0.5 l/side) or latrunculin A (250 ng/0.5 l/side) into amygdala 30 min or 10 min before conditioned pairing blocked the enhancement of Arc/ Arg3.1 protein at synaptosomal membrane fractions of the amygdala induced by CMW (A: vehicle, 193.5 Ϯ 32.5%; Y27632, 71.1 Ϯ 19.7% of control, n ϭ 5, F (2,14) ϭ 6.442, p ϭ 0.0126; B: vehicle, 165.3 Ϯ 20.3%; Latrunculin A, 87.6 Ϯ 22.0% of control, n ϭ 3-4; F (2,10) ϭ 5.502, p ϭ 0.0314; Fig. 3 A, B , right panels), but they had no effects on Arc/Arg3.1 protein expression in amygdalar homogenates (A: vehicle, 219.8 Ϯ 43.2%; Y27632, 203.5 Ϯ 16.8% of control, n ϭ 3-4, F (2,9) ϭ 7.64, p ϭ 0.0174; B: vehicle, 164.3 Ϯ 7.43%; Latrunculin A, 174.8 Ϯ 26.2% of control, n ϭ 5, F (2,14) ϭ 6.026, p ϭ 0.0154; Fig. 3 A, B, left panels) .
Next, we determined the effect of NMDA receptor antagonist D-AP5 on CMW-induced increase in Arc/Arg3.1 at amygdalar synapses. As shown in Figure 3 , bilateral injection of D-AP5 (4 g/0.5 l/side) into amygdala 10 min before conditioned pairing resulted in the reduction of Arc/Arg3.1 protein expression both in amygdalar homogenates (vehicle, 184.2 Ϯ 14.8%; D-AP5, 108.0 Ϯ 6.2% of control, n ϭ 4 -6, F (2,15) ϭ 14.61, p ϭ 0.0005; Fig. 3C , left) and in the synaptosomal membrane fractions of amygdala (vehicle, 155.3 Ϯ 13.7%; D-AP5, 52.7 Ϯ 13.2% of control, n ϭ 4 -6; F (2,14) ϭ 23.44, p Ͻ 0.0001; Fig. 3C, right) , consistent with previous finding that NMDA receptor antagonists block the induction of Arc/Arg3.1 mRNA transcription and targeting to dendrites induced by HFS of the perforant path of hippocampus (Steward and Worley, 2001; Huang et al., 2007) . Taken together, these results clearly demonstrate that actin po- lymerization is required for the targeting of Arc/Arg3.1 to synapses, supporting previous findings that actin polymerization plays a critical role in Arc mRNA targeting to synaptic sites in response to HFS of the dentate gyrus (Huang et al., 2007) .
In vivo knockdown of amygdalar Arc/Arg3.1 blocked place aversion behavior induced by conditioned morphine withdrawal Substantial evidence demonstrates that Arc/Arg3.1 is necessary for a variety of hippocampus-dependent and -independent memories (Guzowski et al., 2000; Plath et al., 2006) . To test whether Arc/Arg3.1 protein is also required for CPA formation, we used a lentivirus expressing short-hairpin (sh) RNA (Arc/Arg3.1-shRNA) to knock down Arc/Arg3.1 mRNA in synapses of the amygdala (Rial Verde et al., 2006) . We first in vitro examined the inhibitory effect of Arc/ Arg3.1-shRNA on Arc/Arg3.1 protein expression in rat primarily cultured cortex neurons. Primary cortex neurons were infected with either control shRNA or Arc/Arg3.1-shRNA in a 20:1 molar ratio. After 12 h virus infection, the cells were stimulated with forskolin for 3 h and then harvested for Western blot analysis with Arc/Arg3.1 antibody. As shown in Figure 4 , infections of primary cortex neurons with Arc/Arg3.1-shRNA resulted in a significant reduction of Arc/ Arg3.1 protein expression compared with neurons infected with control shRNA (control shRNA, 100 Ϯ 7.06%; Arc/Arg3.1 shRNA, 13.1 Ϯ 5.90%; n ϭ 5, t (8) ϭ 8.948, p Ͻ 0.0001) (Fig. 4A,C, left) .
Next, we examine the effect of in vivo knockdown of Arc/ Arg3.1 protein expression using Arc/Arg3.1-shRNA on CMWinduced place aversion. Animals were received bilateral infusions of lentivirus expressing Arc/Arg3.1-shRNAs with high-titer stocks (5 ϫ 10 8 Ϫ1 ϫ 10 9 TU/ml) or a control shRNAs into the amygdala. Two weeks after virus infusion, the animals were trained using place aversion conditioning paradigm. After CPA test, animals were killed and their brains were isolated and sectioned to slices for detecting the sites infected by virus through visualizing GFP under a fluorescence microscope. It was found that most neurons in the BLA and the CeA of the amygdala were positive for GFP, indicating that bilateral intra-amygdala injections of lentivirus resulted in selective expression of Arc/Arg3.1-shRNAs in the BLA and CeA of the amygdala (Fig. 4 B) . As shown in the right panel of Figure 4C , Arc/Arg3.1-shRNAs-infected animals displayed a significantly lower aversion score than control shRNAs-infected and vehicle-injected animals (aversion score: control shRNA, Ϫ380.9 Ϯ 31.8 s, Arc/Arg3.1 shRNA, Ϫ86.9 Ϯ 44.7 s; n ϭ 12; t (22) ϭ 5.36, p Ͻ 0.0001), indicating that knockdown of Arc/Arg3.1 expression in the amygdala impaired CPA formation. Together, these data demonstrate that Arc/Arg3.1 expression in the amygdala, specifically in the BLA and CeA, may be critically important for CPA formation.
In vivo knockdown of amygdalar Arc/Arg3.1 impaired conditioned morphine withdrawal-induced AMPA receptor endocytosis Accumulating data demonstrate that trafficking of AMPARs at synapses plays an important role in the expression of synaptic plasticity (Malinow and Malenka, 2002; Kalivas et al., 2005) . F-actin and AMPA receptors are colocalized in dendritic spines (Allison et al., 1998) and postsynaptic F-actin are involved in a dynamic process required to maintain AMPAR-mediated transmission (Kim and Lisman, 1999) . Recent in vitro studies in dissociated hippocampal neurons and slice cultures also reveal that Arc/Arg3.1 can modulate AMPA receptor trafficking by facilitating AMPA receptor endocytosis Rial Verde et al., 2006; Shepherd et al., 2006) . These findings, together with our observations that the newly expressed Arc/Arg3.1 protein colocalizes with F-actin at synapses of the amygdala raise the possibility that actin polymerization may regulate AMPAR trafficking by Arc/Arg3.1-facilitated AMPAR endocytosis and thereby contribute to synaptic plasticity and behavioral adaptations. To investigate the mechanisms by which Arc/Arg3.1 protein contributes to CPA formation, we thus explored whether the Arc/Arg.31 protein was involved in CMW-induced AMPAR receptor endocytosis. To do this, we first examined the effect of CMW on the distribution of synaptic AMPA receptors in the amygdala using BS 3 cross-linking assay (Boudreau and Wolf, 2005) . BS 3 is a membrane-impermeable protein cross-linking agent and has been shown to selectively cross-link cell surface but not intracellular receptors (Boudreau and Wolf, 2005) . As surface receptors and BS 3 form high molecular weight aggregates, it can be distinguished using SDS-PAGE and Western blotting. Rats were killed at 0.5 and 1 h after CMW. Amygdalar tissues were Figure 3 . Effects of prepairing intra-amygdala injections of ROCK inhibitor Y27632, actin polymerization inhibitor latrunculin A, or NMDA receptor antagonist D-AP5 on Arc/Arg3.1 protein levels in homogenates and synaptic membrane fractions of amygdala isolated from rats 1 h after CMW. A, Intra-amygdala injections of Y27632 blocked enhancement of Arc/Arg3.1 protein expression in the synaptic membrane fractions of amygdala (right), but had no effect on increase in Arc/Arg3.1 protein expression in the homogenates of amygdala (left). B, Intra-amygdala injections of latrunculin A attenuated Arc/Arg3.1 expression in the synaptic membrane fractions of amygdala (right), but had no effect on increase in Arc/Arg3.1 protein expression in the homogenates of amygdala (left). C, Intraamygdala injections of the NMDA receptor antagonist D-AP5 blocked enhancement of Arc/Arg3.1 protein expression in both the homogenates (left) and the synaptic membrane fractions (right) of amygdala.ErrorbarsrepresentmeanϮSEM.*pϽ0.05,**pϽ0.01,***pϽ0.001,comparedwith the corresponding control groups, one-way ANOVA with Newman-Keuls post hoc test. Homo, Homogenate fraction; Con, control; Veh, vehicle, Latr, Latrunculin A. isolated and dissected quickly and treated with BS 3 as described in Materials and Methods. Immunoblot analysis of AMPARs in cross-linked tissue revealed that the surface to intracellular receptor (S/I) ratio of GluR1-and GluR2-containing AMPARs were significantly decreased at 1 h but not at 0.5 h after CMW (GluR1: control, 100 Ϯ 6.19%, n ϭ 11; 0.5 h, 92.2 Ϯ 10.75%, n ϭ 5; 1 h, 54.7 Ϯ 12.04%, n ϭ 11; F (2,26) ϭ 6.619, p ϭ 0.0051; GluR2: control, 100 Ϯ 5.04%, n ϭ 11; 0.5 h, 102.24 Ϯ 14.29%, n ϭ 5; 1 h, 59.65 Ϯ 9.31%, n ϭ 6; F (2,21) ϭ 7.383, p ϭ 0.0042; Fig. 5 A, B , left panels), indicative of a decrease in GluR1-and GluR2-containing AMPAR surface expressions and an increase of their intracellular expressions. No significant differences in the levels of GluR1-and GluR2-containing AMPAR total protein were found between any of the experimental groups, quantified by summing the optical densities of surface and intracellular bands and normalizing to total protein in the lanes (GluR1, F (2,26) ϭ 0.4146, p ϭ 0.6652; GluR2, F (2,21) ϭ 0.4776, p ϭ 0.6275; Fig. 5 A, B, right panels) . These results indicate that endocytosis of GluR1-and GluR2-containing AMPAR occurred at 1 h but not 0.5 h after CMW.
Next, we examined the effect of in vivo knockdown of Arc/ Arg3.1 protein expression with Arc/Arg3.1-shRNA on CMWinduced GluR1-and GluR2-containing AMPAR endocytosis. Animals received bilateral injections of lentivirus expressing Arc/ Arg3.1-shRNAs with high-titer stocks (5 ϫ 10 8 Ϫ1 ϫ 10 9 TU/ml) or control shRNAs into the amygdala. Two weeks later, all animals were trained using place aversion conditioning paradigm. Rats were killed 1 h after CMW and BS 3 cross-linking assay was used to distinguish surface and intracellular AMPAR pools in the amygdala. As shown in Figure 5 , C and D, animals expressing Arc/Arg3.1-shRNA exhibited a significant increase in the surface to intracellular ratio for both GluR1-contining AMPARs (control shRNA, 100 Ϯ 9.90%; Arc/Arg3.1 shRNA, 192.01 Ϯ 12.18%; n ϭ 5, t (8) ϭ 5.863, p ϭ 0.00038) and GluR2-containing AMPARs (control shRNA, 100 Ϯ 17.68%; Arc/Arg3.1 shRNA, 202.31 Ϯ 15.54%; n ϭ 5, t (8) ϭ 4.346, p ϭ 0.00246), when compared with animals expressing control shRNAs. No differences of total AMPARs expression were detected between any of the experimental groups, quantified by summing the optical densities of surface and intracellular bands and normalizing to total protein in the lanes (GluR1, t (8) ϭ 0.8317, p ϭ 0.43; GluR 2 , t (8) ϭ 1.073, p ϭ 0.31). These results demonstrate that the knockdown of synaptic Arc/Arg3.1 with Arc/Arg3.1-shRNAs reduces AMPAR endocytosis, supporting the idea that Arc/Arg3.1 plays an essential role in regulation of AMPAR endocytosis in response to CMW. Thus, in agreement with previous observations in vitro Rial Verde et al., 2006; Shepherd et al., 2006) , the present study demonstrates that Arc/Arg3.1 also modulates AMPAR trafficking by facilitating AMPA receptor endocytosis in vivo.
Intra-amygdala injection of
Tat-GluR2 3Y , a GluR2-derived peptide, prevented both the formation of conditioned place aversion and the endocytosis of AMPARs induced by conditioned morphine withdrawal The findings that in vivo knockdown of Arc/Arg3.1 with Arc/ Arg3.1-shRNA disrupts CPA formation and blocks GluR1-and GluR2-containing AMPAR endocytosis imply that AMPAR endocytosis may be tightly implicated in CPA formation. To confirm that the disruption of CPA by Arg/Arg3.1 shRNA is attributed to its prevention of AMPAR endocytosis, we determined the role of AMPAR endocytosis in CPA formation using a synthetic peptide derived from rat GluR2 carboxyl tail (TatGluR2 3Y : YGRKKRRQRRRYKEGYNVYG), which has been shown to specifically block regulated, but not constitutive, AM-PAR endocytosis (Ahmadian et al., 2004) . We first determined whether AMPARs were implicated in CPA formation. Rats were bilaterally injected with vehicle or AMPAR antagonist CNQX into amygdala 10 min before CMW. Animals injected with CNQX (30 nmol/0.5 l/side) exhibited a significantly lower place aversion score relative to those injected with vehicle (aversion score: vehicle, Ϫ285.4 Ϯ 30.9 s, n ϭ 8; CNQX, Ϫ62.7 Ϯ 36.4 s, n ϭ 10; t (16) ϭ 4.523, p ϭ 0.00035; data not show), indicating that AMPARs play a crucial role in the formation of CPA, consistent with previous studies that local or systematic injection of CNQX could suppress CPA behaviors (Watanabe et al., 2002; Kawasaki et al., 2005) .
Next, we determined whether AMPAR endocytosis was required for CPA formation. To do this, we tested the effect of intra-amygdala injection of Tat-GluR2 3Y on CPA formation. Bilateral intra-amygdala injection of Tat-GluR2 3Y (15 pmol/ 0.5 l/side) 1 h before conditioned pairing yielded a significant reduction of place aversion scores compared with bilateral intraamygdala injection of inactive control peptide Tat-GluR2 3S (aversion score: Tat-GluR2 3S, Ϫ308.5 Ϯ 26.9 s, n ϭ 13; TatGluR2 3Y , Ϫ92.3 Ϯ 23.1 s, n ϭ 14; t (25) ϭ 6.117, p Ͻ 0.0001; Fig 6 A), indicative of a critical role of AMPAR endocytosis in CPA formation. The results are consistent with previous studies that Tat-GluR2 3Y suppressed drugs of abuse-induced associative learning such as behavior sensitization and cue-induced drug relapse to drug seeking (Brebner et al., 2005; Van den Oever et al., 2008) .
To further confirm that disruption of CPA formation by Tat-GluR2 3Y is attributed to its blockade of GluR2-containg AMPAR endocytosis, next, we examined the effect of Tat-GluR2 3Y on the endocytosis of GluR2-containing AMPARs induced by CMW. As shown in Figure 6 B, indeed, bilateral intra-amygdala injection of Tat-GluR2 3Y (15 pmol/0.5 l/side) but not inactive control peptide GluR2 3S 60 min before CMW completely abolished the endocytosis of GluR2-containing AMPARs (Tat-GluR2 3S , 52.77 Ϯ 5.45%; Tat-GluR2 3Y , 97.11 Ϯ 17.89% of control, n ϭ 5-6; F (2,15) ϭ 5.229, p ϭ 0.0216). CMW also led to endocytosis of GluR1-containg AMPARs and this effect could be blocked by knockdown of Arc/Arg3.1 protein with Arc/ Arg3.1-shRNA (Fig. 5) . Since endogenous GluR1 and GluR2 subunits emerge mainly as GluR1/GluR2 heteromers (Wenthold et al., 1996) and GluR2 acts as dominant subunits to control regulated GluR1/GluR2 heteromeric AMPAR endocytosis (Ahmadian et al., 2004; Lee et al., 2004; Isaac et al., 2007) , we thus tested the effect of Tat-GluR2 3Y on CMW-induced GluR1-containg AMPA endocytosis. As expected, bilateral intra-amygdala injection of TatGluR2 3Y (15 pmol/0.5 l/side) but not inactive control peptide GluR2 3S 60 min before CMW also completely abolished the endocytosis of GluR1-containing AMPARs (TatGluR2 3S , 50.06 Ϯ 9.27%; Tat-GluR2 3Y , 117.23 Ϯ 23.20% of control, n ϭ 5-7; F (2,16) ϭ 5.405, p ϭ 0.0182) (Fig. 6C) . No significant differences in the levels of GluR1 and GluR2 total protein were found between any of the experimental groups, quantified by summing the optical densities of surface and intracellular bands and normalizing to total protein in the lanes (GluR1, F (2,16) ϭ 0.1140, p ϭ 0.8930; GluR2, F (2,15) ϭ 0.9024, p ϭ 0.4296; Fig. 6B,C) . These results confirm that AMPARs endocytosis was indeed blocked by Tat-GluR2 3Y .
Tat-GluR2 3Y peptide does not alter GluR2 or GluR1 surface expression under baseline conditions and has no effects on Arc/Arg3.1 protein expression and translocation To confirm that Tat-GluR2 3Y peptide specifically acts on AM-PAR itself but not on upstream molecules of AMPAR internalization and has no effect on AMPAR surface expression under baseline conditions, we thus tested whether GluR2 or GluR1 surface expressions were altered with Tat-GluR2 3Y injection in the absence of CMW and whether Arc expression and synaptic translocation are still induced by CMW in the presence of Tat-GluR2 3Y peptide. Naive rats were injected with Tat-GluR2 3Y peptide into the amygdala and killed after 2 h. Isolated amygdalar tissues were used for BS 3 cross-linking and Western blotting analysis. One-way ANOVA analysis showed no significant differences in the levels of GluR2 (Fig. 7A) or GluR1 (Fig. 7B ) S/I ratio between any of the experimental groups (GluR2, F (2,16) ϭ 0.4068, p ϭ 0.6734, n ϭ 5-6; GluR1, F (2,17) ϭ 0.2854, p ϭ 0.7557, n ϭ 6). These results confirm that preinjection of Tat-GluR2 3Y peptide into the amygdala have no effects on both GluR2-and GluR1-containing AMPAR surface expression under baseline conditions.
Since in vivo knockdown of amygdalar Arc/Arg3.1 with Arc/ Arg3.1-shRNA also prevented GluR1-and GluR2-containing AMPAR endocytosis (Fig. 5C,D) , it raises the possibility that the blockade of AMPAR endocytosis by Tat-GluR2 3Y peptide might be induced by altering expression or synaptic translocation of Arc/Arg3.1 protein. Thus, we next tested whether Arc/Arg3.1 was still expressed and driven into synaptic compartments of the amygdala in the presence of the GluR2 peptide during conditioned opiate withdrawal. As shown in Figure 7 , C and D, a significant increase in Arc/Arg3.1 protein expression was detected in both the homogenates (F (3,20) ϭ 4.408, p ϭ 0.0181, n ϭ 5-6) and synaptosomal membrane fractions (F (3,20) ϭ 6.136, p ϭ 0.0051, n ϭ 5-6) of the amygdala in the presence of the Tat-GluR2 3Y peptide during conditioned opiate withdrawal. This indicates that preinjection of Tat-GluR2 3Y peptide into the amygdala have no effects on both Arc/Arg3.1 protein expression and transloca- Figure 5 . Knockdown of the Arc/Arg3.1 protein in the amygdala inhibited GluR1-and GluR2-containing AMPAR endocytosis induced by CMW. A, B, CMW resulted in reduction of surface GluR1-and GluR2-containing AMPARs. Top panels show representative blots of surface (S) and internalized (I) GluR1-(A) and GluR2-containing AMPARs (B) from amygdalar tissues prepared from rats 0.5 and 1 h after conditioned morphine withdrawal. Bottom panels show quantification of surface/internal GluR1-and GluR2-containing AMPARs levels from Western blot data. Error bars represent mean Ϯ SEM. **p Ͻ 0.01, compared with the corresponding saline-treated control group, one-way ANOVA with Newman-Keuls post hoc test. C, D, In vivo knockdown of Arc/Arg3.1 inhibited decreases in surface GluR1-and GluR2-containing AMPARs induced by CMW. Top panels show representative blots of surface and internalized GluR1-(C) and GluR2-containg AMPARs (D) from amygdalar tissues prepared from rats 1 h after conditioned morphine withdrawal. Bottom panels show quantification of the S/I ratios of GluR1-and GluR2-containing AMPARs from Western blot data. Error bars represent mean Ϯ SEM. **p Ͻ 0.01, ***p Ͻ 0.001, compared with the control shRNA-infected groups, two-tailed Student's t test. Total proteins (SϩI, normalized to total protein in the lane) levels of GluR1-and GluR2-containing AMPARs have no changes in all groups.
tion to synaptic compartments of the amygdala, suggesting that Tat-GluR2 3Y peptide specifically acts on AMPARs.
Conditioned morphine withdrawal elicited occlusion of longterm depression in the amygdala
Our data indicate that CMW induces endocytosis of AMPARs through a mechanism involving an increase in Arc/Arg3.1 expression. Endocytosis of AMPARs usually results in the expression of various forms of LTD in various brain areas (Brebner et al., 2005; Yu et al., 2008) . Hence, we hypothesize that CMW may induce a form of LTD, which may prevent or occlude further induction of LTD in response to stimulus. To test this hypothesis, we measured excitatory synaptic transmission in slices of the amygdala prepared from rats in which CPA was induced by CMW. As shown in Figure 8 A, reliable LTD was induced by LFS (1 Hz, 900 pulses) in the amygdalar slices prepared from naive rats (83.15 Ϯ 6.07%, 14 slices from seven rats). Preincubation of slices with the Tat-GluR2 3Y peptide (1.5 M), while not affecting basal synaptic transmission (data not shown), prevented the expression of LTD (102.15 Ϯ 1.95%, eight slices from five rats). The control inactive peptide Tat-GluR2 3S failed to affect LTD (76.50 Ϯ 11.81%, six slices from three rats). These results are consistent with previous studies showing that the Tat-GluR2 3Y peptide prevent the regulated, but not constitutive AMPAR endocytosis (Ahmadian et al., 2004) and thereby block the expression of LTD, without affecting the basal synaptic transmission (Ahmadian et al., 2004; Brebner et al., 2005; Yu et al., 2008) , and support the idea that LFS-induced LTD relies on endocytosis of GluR2-containg AMPARs (Ahmadian et al., 2004; Rial Verde et al., 2006) . LFS also induced LTD in the slices prepared from the rats that underwent UMW (89.40 Ϯ 4.64%, nine slices from four rats) or saline-pairing control rats (80.48 Ϯ 14.48%, eight slices of five rats; Fig. 8 B) . However, LFS failed to induce LTD in the amygdalar slices from rats that underwent CMW (101.43 Ϯ 8.87%, six slices from five rats; Fig. 8C ), consistent with the idea that CMW induces a form of LTD that would occlude further induction of LTD by LFS if the LTDs share similar mechanisms. CMW induces GluR2-containing AMPAR endocytosis via Arc/ Arg3.1-dependent mechanism (Fig. 5) , implying that it may induce an LTD via GluR2-dependent endocytosis of AMPARs. If this is the case, blockade of the CMW-induced LTD with TatGluR2 3Y , which show blockade of LTD expression, without affecting either the basal synaptic transmission or the expression of LTP in various brain areas (Ahmadian et al., 2004; Brebner et al., 2005) , could restore the LFS-induced LTD. As predicated, LFS elicited a reliable LTD in the amygdalar slices prepared from the rats that were injected Tat-GluR2 3Y intravenously (15 mol/kg, i.v.) 24 h before CMW (74.16 Ϯ 5.87%, nine slices of four rats; Figure 6 . Intra-amygdala injections of Tat-GluR2 3Y prevented the formation of conditioned place aversion and the endocytosis of GluR1-and GluR2-containing AMPARs induced by conditioned morphine withdrawal. A, Left, Bilateral microinjection of Tat-GluR2 3Y but not Tat-GluR2 3S into the amygdala blocked CPA formation induced by CMW; right, the image of schematic illustration of Tat-GluR2 3S and Tat-GluR2 3Y injection sites in the amygdala. E, Tat-GluR2 3S injection; •, Tat-GluR2 3Y injection. Error bars represent mean Ϯ SEM. ***p Ͻ 0.001, compared with the Tat-GluR2 3S -injected groups, two-tailed Student's t test. B, C, Tat-GluR2 3Y peptide prevented the endocytosis of GluR2-and GluR1-containing AMPARs induced by conditioned morphine withdrawal. Top panels show representative blots of surface (S) and internalized (I) GluR2-and GluR1-containing AMPARs from amygdalar tissues prepared from rats 1 h after conditioned morphine withdrawal. Bottom panels show quantification of surface/internal GluR2-and GluR1-containing AMPARs levels from Western blot data. Error bars represent mean Ϯ SEM. *p Ͻ 0.05, compared with the corresponding saline-treated control group, one-way ANOVA with Newman-Keuls post hoc test. Fig. 8 D) . However, LFS was unable to induce LTD in the amygdalar slices prepared from rats that were injected with the inactive control peptide GluR2 3S before CMW (105.99 Ϯ 12.82%, 10 slices from four rats; Fig. 8 D) . These results strongly support that CMW elicits an LTD in the amygdala via endocytosis of GluR2-containg AMPARs as a result of enhancement of Arc/Arg3.1 protein expression and suggest that like other forms of experiencedependent behavioral plasticity, CPA behavior may be due, at least in part, to modifications of synaptic efficacy in critical neural circuits. Overall, our results, together with the observations that intra-amygdala injection of Tat-GluR2 3Y also disrupts CMW-induced CPA, suggest that the mechanisms that modulate LTD are critical for CPA formation.
Discussion
Synaptic actin rearrangements have been shown to play a crucial role in the stabilization of synaptic plasticity and the formation of long-term memory (Matus, 2000; Marie-Claire et al., 2004) . However, molecular mechanisms underlying actin polymerization in regulation of synaptic plasticity and memory remain unclear. In this study, by using CPA, a model for associative learning, we provided the first in vivo evidence that behavior training triggers Arc/Arg3.1 translocation at the synapses through actin polymerization, and Arc/Arg3.1 in turn regulates synaptic AMPA receptor endocytosis, thereby leading to amygdalar synaptic depression and aversive memory formation. Actin rearrangement, Arc/Arg3.1 expression, and AMPA receptor trafficking are three critical molecular events involved in synaptic plasticity and memory formation. The present study reveals for the first time that Arc/ Arg3.1 is a crucial mediator for actin polymerization in regulating synaptic plasticity and memory, and thus our findings underscore the unknown details of how actin polymerization mediates synaptic plasticity and memory.
Actin polymerization is required for the enhancement of Arc/ Arg3.1 protein expression at Amygdalar synapses Recently, we showed that synaptic actin polymerization in the amygdala was required for aversive memory information ). However, the molecular mechanisms by which actin polymerization contributes to the aversive memories of morphine withdrawal remain to be established. The present study demonstrated that actin polymerization was involved in the enhancement of Arc/Arg3.1 protein expression at amygdalar synapses in response to CMW. This involvement was supported by the following observations. First, synaptic enhancement of Arc/ Arg3.1 protein occurred later than that of synaptic actin polymerization. Actin polymerization within synapses occurred at 0.5 h after CMW (Fig. 1) ; however, increased Arc/ Arg3.1 protein at synapses could be examined only at 1 h after CMW (Fig. 2 D) , although increase in Arc/Arg3.1 protein expression in the amygdala was observed at 0.5 h. This suggests a translocation of Arc mRNA from soma to synapse. Second, prior to conditioned pairing of intra-amygdala injection of D-AP5, an NMDA receptor antagonist that blocked actin polymerization (Fig.  1B) (Huang et al., 2007) , also disrupted the enhancement of Arc/ Arg3.1 protein in the synaptic sites (Fig. 3C) . Third, direct evidence to support the involvement of actin polymerization in the enhancement of Arc/Arg3.1 protein in the synaptic sites was that blockade of actin polymerization with RhoA kinase inhibitor Y27632 and the F-actin polymerization inhibitor latrunculin A abolished the enhancement of Arc/Arg3.1 protein at the amygdalar synapses (Fig.  3A,B) . These results clearly indicate that actin polymerization are required for the targeting of Arc/Arg3.1 mRNA to synapses in response to conditioned pairing, consistent with a previous study showing that actin polymerization plays a critical role in Arc mRNA targeting to active synapse in response to HFS known to cause LTP (Huang et al., 2007) . Intriguingly, a recent study shows that Arc/ Figure 7 . Tat-GluR2 3Y peptide does not alter GluR2 or GluR1 surface expression under baseline conditions and has no effects on both Arc/Arg3.1 protein expression and translocation to synaptic membrane induced by conditioned morphine withdrawal. A, B, Top panels show representative blots of surface (S) and internalized (I) GluR2-(A) and GluR1-(B) containing AMPARs from amygdalar tissues prepared from rats 2 h after injection. Bottom panels show quantification of surface/internal GluR2-and GluR1-containing AMPARs levels from Western blot data. Error bars represent mean Ϯ SEM, one-way ANOVA with NewmanKeuls post hoc test. C, D, Tat-GluR2 3Y had no effects on either Arc/Arg3.1 protein expression or synaptic translocation. Top panels show representative blots of Arc/Arg3.1 protein levels in the homogenates and the synaptosomal membrane fractions prepared from amygdalar tissues prepared from rats 1 h after conditioned morphine withdrawal. Bottom panels show quantification of Arc/Arg3.1 protein expression in the homogenates and the synaptosomal membrane fractions from Western blot data. Error bars represent mean Ϯ SEM. *p Ͻ 0.05, **p Ͻ 0.01, compared with the corresponding saline-treated control group, one-way ANOVA with Newman-Keuls post hoc test.
formation. Our findings are consistent with previous studies showing that AMPAR endocytosis plays a crucial role in some forms of behavior adaptations induced by drug exposure but extend these findings by revealing a role of Arc/Arg3.1 in AMPAR endocytosis.
In this study, we also found that CMW resulted in occlusion of LTD induction in the amygdala and this occlusion was rescued by intravenous injection of Tat-GluR2 3Y before conditioned pairing. These results suggest that LTD, expressed via a decrease in synaptic AMPARs through GluR2-dependetn endocytosis, occurs in amygdalar neurons as a result of enhancement of synaptic Arc/Arg3.1 expression. The findings, together with the observations that intra-amygdala injection of Tat-GluR2 3Y before conditioned pairing prevented the expressions of both LTD and CPA, provides an evidence for the involvement of GluR2 endocytosismediated LTD within the amygdala in the acquisition of aversive memory associated with morphine withdrawal. This is different from the findings obtained from fear memory, another amygdalar-dependent emotional learning, in which the mechanisms of LTP are recruited (Tsvetkov et al., 2002; Maren, 2005) . In support of our findings, GluR2 endocytosis-mediated LTD within the nucleus accumbens and the prefrontal cortex is linked to some forms of experience-dependent behavioral plasticity such as behavioral sensitization (Thomas et al., 2001; Brebner et al., 2005) and cue-induced relapse to heroin-seeking ( Van den Oever et al., 2008) . Therefore, the studies of us and others suggest that LTD may be required for some forms of drug-associated memory formation. Overall, the present study reveals that Arc/ Arg3.1-mediated AMPAR endocytosis and the resulting synaptic depression in amygdala is crucial for the formation of aversive memory associated with morphine withdrawal and thereby suggests that amygdala can contribute to the formation of aversive memories by distinct mechanisms.
In summary, we demonstrate that essential molecular events occurred at amygdalar synapses for aversive memories associated with drug withdrawal, which are initiated by activation of NMDA receptors, leading to fast increase of actin polymerization to help the increase of Arc/Arg3.1 protein at synaptic sites, and thereby enabling LTD and memory formation by Arc/Arg3.1-mediated AMPAR endocytosis. These findings underscore a part of the details of how actin rearrangements contribute to synaptic plasticity and long-term memory.
